SRSF2 mutations occur in 5-15% of acute myeloid leukemia (AML) and ~15% of myelodysplastic neoplasms (MDS), are enriched in elderly/secondary AML, and lack mutation-directed therapy. We aimed to identify vulnerabilities in MDS/AML with SRSF2 mutations. Ex vivo drug-sensitivity testing of bone marrow cells from AML pati...
S. Eldfors, Sumit Rai, Vineet Sharma et al.· Leukemia· 0 citations
The convergence of diagnostics and therapeutics, known as cancer theranostics, has become the backbone of 21st-century precision oncology. In the past decade, exponential progress in the engineering of nano-biosensors, nanorobotic actuation, and molecular biomarker profiling has allowed for the interrogation of tumors...
Manvi Rawat, Murari Kumar Jha, P. K. Agrawal et al.· Discover Sensors· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.